Enterprise value to EBITDA forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR
This article provides the enterprise value to EBITDA forward for Capricor Therapeutics, Inc. (NASDAQ: CAPR) as presented on TradingView. It includes basic company information and navigational links typical of a financial data platform.
Capricor Therapeutics (NASDAQ:CAPR) Is In A Strong Position To Grow Its Business
This article analyzes Capricor Therapeutics (NASDAQ:CAPR), asserting that it is well-positioned for business growth. The analysis likely delves into the company's financials, pipeline, and market position to support this optimistic outlook.
Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript
This earnings call transcript summarizes Capricor Therapeutics Inc.'s Q4 2025 financial results and clinical developments. Key positive points include FDA acceptance of their BLA for Jeremiasel (targeting August 2026 action), promising HOPE 3 trial results for Duchenne muscular dystrophy, and a strong cash position. Negatively, the company reported zero revenue for the quarter, increased operating expenses, and a significant net loss, while facing manufacturing scaling challenges.
Enterprise value to revenue forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR
This article displays the "Enterprise value to revenue forward" for Capricor Therapeutics, Inc. (NASDAQ: CAPR) on TradingView. It indicates that the market was closed at the time of viewing, with no trades observed. The content provides basic financial information access for the company within the health technology sector.
Price to sales forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR
The article mentions the "Price to sales forward" metric for Capricor Therapeutics, Inc. (NASDAQ: CAPR). It appears to be a financial data point available on TradingView, within the company's financial overview. The content provided is minimal, focusing on navigation and data attribution.
Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal
Capricor Therapeutics (CAPR) shares have experienced significant short-term pressure due to removal from Russell indices and upcoming FDA advisory committee discussions on its Duchenne muscular dystrophy therapy, Deramiocel. Despite this, the company's long-term returns remain strong, and analysts view the stock as potentially 58% undervalued. The article suggests that recent news might present a buying opportunity, given its strong cash position and potential future milestones, though regulatory delays and rising costs pose risks.
CAPR - Capricor Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Capricor Therapeutics Inc (CAPR), including its stock performance, key financial metrics, and volatility. It covers data such as market capitalization, income, sales, insider and institutional ownership, and various performance indicators. The report also highlights options and short interest data for the company.
Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal
Capricor Therapeutics (CAPR) shares have dropped following its removal from Russell indices, despite strong long-term returns. The article suggests CAPR could be 58% undervalued, with a fair value of $54.67, driven by expectations for its Duchenne muscular dystrophy cell therapy candidate, Deramiocel, and a strong cash position. However, regulatory delays or funding pressures pose risks to this bullish outlook.
Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal
Capricor Therapeutics (CAPR) stock is under pressure due to its removal from Russell indices and upcoming FDA discussions on its Duchenne muscular dystrophy therapy, Deramiocel. Despite short-term price drops, the stock has shown strong long-term returns. Simply Wall St's analysis suggests Capricor is 58% undervalued at $23.07, with a fair value of $54.67, driven by expectations of sharp revenue growth, higher margins, and potential milestone payments.
Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR) - Recover Losses - Contact Levi & Korsinsky Before September 15, 2025
A class action lawsuit has been filed against Capricor Therapeutics, Inc. (CAPR) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders who purchased stock between October 9, 2024, and July 10, 2025. The lawsuit alleges securities fraud, claiming Capricor made misleading statements regarding its lead cell therapy candidate, deramiocel, despite knowing it faced issues with FDA approval. This followed the FDA's denial of a Biologics License Application on July 11, 2025, causing a significant drop in Capricor's stock price.
Capricor Therapeutics, Inc. Financial Disclosures & Filings
This page provides a comprehensive list of Capricor Therapeutics, Inc.'s financial disclosures and regulatory filings, offering insights into the company's performance and strategy. Key documents include earnings reports, corporate presentations, and updates on the progress of their lead drug candidate, deramiocel, particularly concerning its FDA review and clinical trial results for Duchenne Muscular Dystrophy (DMD). The financial disclosures detail the company's efforts toward commercial readiness and address legal disputes, providing a historical overview of significant corporate events and regulatory milestones.
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review
Capricor Therapeutics (CAPR) shares recently hit a four-month low following news that two senior executives sold nearly $1.5 million in shares. This comes as the company prepares for a critical FDA review of its Duchenne muscular dystrophy treatment, Deramiocel, with an advisory committee meeting scheduled for July 29, 2026. Despite the executive's stock sales, the company reported positive five-year results from its Hope-2 study and positive Phase 3 Hope-3 results for Deramiocel.
Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4 for Capricor Therapeutics Inc. The filing date is June 29, and the article was published on June 30, 2026. The content includes market data for various indices, commodities, and shares, indicating financial market activity.
Capricor (NASDAQ: CAPR) EVP exercises options and sells 24,100 shares under 10b5-1 plan
Capricor Therapeutics EVP and General Counsel Karen Krasney exercised stock options for 24,100 shares at $3.18 per share and subsequently sold all 24,100 shares in open-market transactions at a weighted average price of $30.38 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Krasney directly holds 30,547 shares of common stock and 31,261 stock options.
Capricor Therapeutics Insiders Sold Shares Worth Over $1.5M
Two Capricor Therapeutics officers, Krasney Karen (EVP, General Counsel) and Anthony Bergmann (Chief Financial Officer), each sold 24,100 shares of common stock for total proceeds of $732,158 each, amounting to over $1.5 million combined. Both sales were executed under Rule 10b5-1 trading plans at a weighted average price of $30.38 per share. Following these transactions, Krasney Karen directly owns 30,547 shares and Anthony Bergmann owns 11,223 shares.
Capricor (NASDAQ: CAPR) CFO sells 24,100 shares under 10b5-1 plan
Capricor Therapeutics CFO Anthony Bergmann exercised stock options to acquire 24,100 shares and subsequently sold all of them in open-market transactions for a weighted average price of $30.38 per share. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Bergmann directly holds 11,223 shares of common stock and 91,980 stock options.
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval
Capricor Therapeutics (CAPR) shares fell 9% following a wider-than-expected Q4 loss. Despite the dip, Wall Street analysts remain optimistic about the approval of the company's lead candidate, Deramiocel, for Duchenne Muscular Dystrophy, with multiple firms raising their price targets. The FDA has resumed its review of Deramiocel's Biologics License Application, with a decision expected by August 22, 2026.
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
This article provides the transcript of Capricor Therapeutics Inc.'s presentation at the Goldman Sachs Healthcare Conference on June 10, 2026. The presentation featured CEO Linda Marvin and CFO AJ Bergen, who discussed the company's progress as a late-stage biotech developing dera male cell therapy. The full transcript details their discussion regarding the company's activities and financial status.
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell 3000E Index
Capricor Therapeutics, Inc. (NasdaqGS: CAPR) has been dropped from the Russell 3000E Index, as reported on MarketScreener. The company, a biotechnology firm focused on developing cell and exosome-based therapeutics for rare diseases, was also dropped from the Russell 3000E Growth Benchmark. This news follows recent developments including mixed financial results and updates on its Duchenne muscular dystrophy therapy.
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell 3000E Growth Benchmark
Capricor Therapeutics, Inc. (NasdaqGS:CAPR) has been dropped from the Russell 3000E Growth Benchmark. This news comes amidst other recent updates for the biotechnology company, including presentations of positive clinical trial data for their lead product candidate, Deramiocel, and their Q1 2026 earnings report, which showed a widening loss.
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi & Korsinsky to Join Class Action Before September 15, 2025
Levi & Korsinsky LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ:CAPR) for alleged securities fraud between October 9, 2024, and July 10, 2025. The lawsuit claims Capricor made false and misleading statements regarding its Duchenne muscular dystrophy drug deramiocel, particularly concerning its ability to obtain FDA approval. This follows the FDA's denial of the Biologics License Application on July 11, 2025, which caused a significant drop in Capricor's stock price.
Capricor Therapeutics (CAPR) Is Down 6.8% After Positive Five-Year HOPE-2 DMD Data And FDA Update
Capricor Therapeutics (CAPR) saw its stock drop by 6.8% despite reporting positive five-year results from its HOPE-2 Open-Label Extension study for Deramiocel in Duchenne muscular dystrophy. The data showed slowed upper limb decline, stable cardiac function, and a favorable safety profile. Investors are anticipating an FDA advisory committee meeting on July 29, 2026, and an August 22, 2026 PDUFA target date for Deramiocel’s biologics license application, which present both a significant opportunity and regulatory risk.
Capricor reports five-year data for Duchenne therapy deramiocel
Capricor Therapeutics announced positive five-year data from its HOPE-2 Open-Label Extension study for deramiocel, a Duchenne Muscular Dystrophy cell therapy. The data, presented at a medical conference, showed a significantly slower decline in upper limb performance and stable cardiac function compared to external comparators. The company's Biologics License Application for deramiocel is currently under FDA review, with a target action date of August 22, 2026.
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
Capricor Therapeutics announced positive five-year data from its HOPE-2 Open-Label Extension (OLE) study and HOPE-3 Phase 3 trial results for Deramiocel in Duchenne Muscular Dystrophy (DMD). The data show Deramiocel attenuated disease progression, preserved cardiac function, and maintained a favorable safety profile. These findings support the ongoing FDA Biologics License Application (BLA) review, with a PDUFA date set for August 22, 2026.
[8-K] CAPRICOR THERAPEUTICS, INC. Reports Material Event
Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) will convene on July 29, 2026, to review its Biologics License Application (BLA) for Deramiocel. This investigational cell therapy is intended for the treatment of Duchenne muscular dystrophy (DMD). The BLA is supported by positive Phase 2 and Phase 3 trial data, with a PDUFA target action date of August 22, 2026.
Capricor Therapeutics to Face FDA Advisory Panel on BLA for Deramiocel; PDUFA Aug 22
Capricor Therapeutics announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) will hold a meeting on July 29, 2026, to review its Biologics License Application (BLA) for Deramiocel. The BLA is supported by positive results from Phase 2 HOPE-2 and HOPE-2-OLE, as well as Phase 3 HOPE-3 studies. The company's BLA remains on track for a PDUFA target action date of August 22, 2026.
FDA schedules advisory meeting for Capricor’s DMD therapy
The FDA has scheduled an advisory committee meeting for July 29, 2026, to discuss Capricor Therapeutics' Biologics License Application for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. The application is supported by positive data from multiple clinical trials, with the FDA's PDUFA target action date set for August 22, 2026. Capricor's stock has seen significant returns over the past year and analysts have a strong buy consensus, despite a recent wider-than-expected Q1 2026 loss.
Capricor Therapeutics Faces Stock Drop Ahead of FDA Advisory Meeting
Capricor Therapeutics (CAPR) experienced a stock drop of about 12% following the announcement that the FDA has scheduled an advisory committee meeting for July 29 to discuss its marketing application for Deramiocel, a Duchenne muscular dystrophy treatment. This comes despite the FDA having accepted a resubmitted application in March, following a previous rejection in July 2025. The company's future approval prospects are now largely dependent on the outcome of this upcoming meeting, influencing current market sentiment and investor confidence.
Capricor Therapeutics Says Deramiocel BLA PDUFA Target Action Date Set For August 22
Capricor Therapeutics announced that the PDUFA target action date for its Deramiocel Biologics License Application (BLA) has been set for August 22. This news was reported by Reuters via TradingView.
FDA panel to review Capricor’s Duchenne drug on July 29
Capricor Therapeutics announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will review its Biologics License Application (BLA) for Deramiocel, a Duchenne muscular dystrophy treatment, on July 29, 2026. The BLA is supported by positive data from Phase 2 and Phase 3 trials, including the HOPE-3 trial which met its primary and key secondary endpoints. The company's BLA remains on track for a PDUFA target date of August 22, 2026, and Deramiocel holds several important regulatory designations.
Capricor faces FDA AdCom panel for Duchenne drug (CAPR:NASDAQ)
Capricor Therapeutics (CAPR) shares fell approximately 12% after the U.S. FDA announced an advisory committee meeting to review the company's marketing application for Deramiocel. This drug is intended to treat Duchenne muscular dystrophy. The meeting was disclosed in a federal notice on Friday.
Capricor Therapeutics Announces FDA Advisory Committee
Capricor Therapeutics announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet on July 29, 2026, to review the company's Biologics License Application (BLA) for Deramiocel. This investigational cell therapy is intended for Duchenne muscular dystrophy (DMD) and has a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. The BLA is supported by positive results from multiple trials, including the Phase 3 HOPE-3 trial, which demonstrated statistically significant skeletal and cardiac benefits.
Form 4 Capricor Therapeutics Inc For: 24 June By Investing.com
This article from Investing.com reports that Capricor Therapeutics Inc. filed a Form 4 for June 24. A Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders (officers, directors, or beneficial owners of more than 10% of a class of equity securities) to report changes in their ownership of the company's securities. The brief article itself does not provide any specific details from the Form 4 filing.
Anthony Bergmann, CFO, sells $27,000 in Capricor Therapeutics stock
Anthony Bergmann, CFO of Capricor Therapeutics (NASDAQ:CAPR), sold 900 shares of company stock for $27,000 after exercising stock options. These sales, executed under a 10b5-1 trading plan, leave him with 11,223 direct shares and 116,080 derivative shares. This news comes as the company faces a larger-than-expected Q1 2026 loss, but anticipates FDA review of its lead product Deramiocel and maintains a "Buy" rating from B.Riley.
Form 4 Capricor Therapeutics Inc For: 24 June By Investing.com
This article from Investing.com is a brief notice about a Form 4 filing for Capricor Therapeutics Inc on June 24. It provides no further details beyond the company and date of the filing, and is largely surrounded by market data, news headlines, and promotional content common on financial news platforms. The core message is simply the existence of this regulatory filing.
Capricor (NASDAQ: CAPR) EVP trades 900 shares in preplanned sale
Capricor Therapeutics EVP and General Counsel Karen Krasney reported preplanned insider transactions, exercising stock options for 900 shares at $3.18 each and subsequently selling those 900 shares on the open market at $30.00 per share. These transactions were executed under a Rule 10b5-1 trading plan established in December 2025. Following these sales, Krasney directly holds 30,547 shares of Capricor common stock.
Capricor (NASDAQ: CAPR) CFO sells 900 shares under Rule 10b5-1 plan
Capricor Therapeutics CFO Anthony Bergmann sold 900 shares of common stock at $30.00 each after exercising options at $3.18 per share. The transactions, which occurred on June 22 and June 24, 2026, were executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these sales, Bergmann directly holds 11,223 shares of Capricor common stock, indicating a routine equity compensation activity rather than a significant change in ownership.
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval
Capricor Therapeutics (CAPR) CEO Linda Marban is confident that their Duchenne Muscular Dystrophy (DMD) therapy, Deramiocel, will receive full FDA approval, rejecting concerns about conditional approval. This optimism follows the FDA's acceptance of their resubmitted application, with a PDUFA decision date set for August 22, causing CAPR stock to have its best week in nearly a month. The company is preparing for a potential launch, with manufacturing facilities capable of treating an increasing number of patients, and clinical data from the Phase 3 Hope-3 trial supporting the efficacy of Deramiocel.
Creek Drive Management Group LLC Buys Shares of 36,000 Capricor Therapeutics, Inc. $CAPR
Creek Drive Management Group LLC acquired a new stake of 36,000 shares in Capricor Therapeutics, valued at approximately $1.04 million, during the fourth quarter. This institutional activity increased Capricor's institutional ownership to 21.68%. Despite the increased investment, the company recently reported a quarterly loss of $0.59 per share, slightly exceeding analyst expectations, and several insiders have sold shares totaling over $1 million in the past quarter.
How (CAPR) Movements Inform Risk Allocation Models
This article analyzes Capricor Therapeutics Inc. (CAPR) stock movements using AI models to inform risk allocation. It highlights a strong near-term sentiment within a long-term strength context, despite a mid-term weak bias. The analysis provides specific trading strategies, including long, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and risk-reward setups.
Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)
Three analysts have issued bullish sentiments on healthcare companies Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR), and Medtronic (MDT). Oppenheimer reiterated a Buy rating for Odyssey Therapeutics with a $40 price target, and also for Capricor Therapeutics with a $54 price target. Wells Fargo maintained a Buy rating on Medtronic with a $102 price target, noting a moderate buy consensus overall for the company.
Capricor Therapeutics Inc (CAPR) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Capricor Therapeutics Inc (CAPR), detailing its current valuation score, market capitalization, and P/E ratio. It notes that the company's P/E ratio is -12.07, significantly below its recent high and above its recent low. The article also mentions that relevant P/B, P/S, and P/CF data have not been disclosed by the company.
Capricor Therapeutics Inc (CAPR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Capricor Therapeutics Inc's (CAPR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also displays current stock performance and market capitalization for CAPR.
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6%
Capricor Therapeutics (CAPR) saw its stock jump 6% as investors awaited a crucial oral argument concerning a legal dispute with Nippon Shinyaku and NS Pharma. The lawsuit, filed by Capricor, alleges that the current distribution agreement for their Duchenne Muscular Dystrophy (DMD) therapy, Deramiocel, creates a pricing issue that could limit patient access through Medicare, Medicaid, and private insurance. An FDA decision on Deramiocel's Biologics License Application is anticipated on August 22, 2026.
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Capricor Therapeutics is actively discussing with the FDA for potential approval of its Duchenne muscular dystrophy cell therapy, deramiocel, utilizing data from its HOPE-3 Phase 3 trial. The company expects a PDUFA date of August 22, 2026, and is preparing for an independent commercial launch despite ongoing litigation with NS Pharma. Capricor also detailed its manufacturing capabilities, pipeline expansion, and strong cash position.
Does FDA Talks And HOPE-3 Data Shift The Bull Case For Capricor Therapeutics (CAPR)?
Capricor Therapeutics (CAPR) is engaging in active FDA discussions following shareholder approval for a Certificate of Incorporation amendment and presenting its Duchenne muscular dystrophy program at a summit. The company's investment narrative hinges on deramiocel securing FDA approval by the August 22, 2026 PDUFA date and becoming a commercially viable product. While recent updates don't alter the core risks of regulatory uncertainty and cash burn, they maintain focus on the critical approval pathway.
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Capricor Therapeutics is actively working towards FDA approval for its Duchenne muscular dystrophy cell therapy, deramiocel, with a PDUFA date of August 22, 2026. The company is preparing for an independent launch after disputes with NS Pharma, building commercial infrastructure and manufacturing capabilities. Capricor also plans to explore deramiocel for other inflammatory and fibrotic diseases and is developing an exosome-based platform.
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Capricor Therapeutics is actively engaged with the FDA for the approval of its Duchenne muscular dystrophy cell therapy, deramiocel, with a PDUFA date set for August 22, 2026. The company reported positive HOPE-3 trial results demonstrating both skeletal and cardiac benefits. Following disputes with former partner NS Pharma, Capricor plans to independently launch deramiocel and is building its commercial and manufacturing infrastructure for a potential U.S. market entry.
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
This article provides the transcript of Capricor Therapeutics Inc's presentation at the Goldman Sachs Healthcare Conference on June 10, 2026. The presentation featured CEO Linda Marvin and CFO AJ Bergen, who discussed the company's background and its late-stage allogeneic cardiac-derived cell therapy, dera male cell, which is awaiting approval for treatment.
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains
Capricor Therapeutics (CAPR) is garnering investor attention ahead of next week's presentation of Phase 3 Duchenne muscular dystrophy (DMD) trial data. The data, focusing on the cell therapy Deramiocel, is expected to reveal benefits for both muscle and cardiac function in DMD patients. The FDA's regulatory review of Deramiocel is ongoing, with a new PDUFA decision date possible in the future.
